Streetbeat News

Price Targets

THRN

TD Cowen analyst Oliver Chen has downgraded Thorne HealthTech (NASDAQ:THRN) from Outperform to Market Perform, while raising the price target from $8 to $10.2.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:30 am

PVH

Telsey Advisory Group has reiterated its 'Outperform' rating on PVH (NYSE:PVH) and maintained its price target of $102.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:24 am

BIG

Telsey Advisory Group analyst Joseph Feldman maintains a 'Market Perform' rating on Big Lots (NYSE:BIG) and raises the price target from $6 to $8.5.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:16 am

BBY

Telsey Advisory Group has maintained its 'Market Perform' rating on Best Buy Co (NYSE:BBY) and raised the price target from $78 to $85.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:15 am

NCNO

Piper Sandler analyst Brent Bracelin maintains a Neutral rating on Ncino (NASDAQ:NCNO) and lowers the price target from $32 to $30.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:14 am

APLS

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $60.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:14 am

WST

Keybanc analyst Paul Knight maintains an Overweight rating on West Pharmaceutical Servs (NYSE:WST) and raises the price target from $415 to $440.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:09 am

STVN

Keybanc analyst Paul Knight maintains an Overweight rating on Stevanato Gr (NYSE:STVN) and raises the price target from $35 to $37.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:08 am

BOX

Keybanc analyst Thomas Blakey maintains an Overweight rating on Box (NYSE:BOX) but lowers the price target from $35 to $33.

Portfolio Pulse from richadhand@benzinga.com

August 30, 2023 | 8:07 am

CLOV

Clover Health Investments Corp. (NASDAQ:CLOV) shares are trading higher due to a recent analyst price target change and a positive quarterly report. The company reported Q2 sales of $513.63 million, beating the analyst consensus estimate of $490.82 million. Clover also issued full-year 2023 EBITDA guidance with losses between $70 million and $120 million, an improvement from the previous estimate. Citigroup analyst Jason Cassorla maintained a Neutral rating for the company and raised the price target from $1 to $1.5.

Portfolio Pulse from Ryan Gustafson

August 29, 2023 | 8:17 pm